Cardiovascular Research Center, TAHA Clinical Trial Group, Shiraz University of Medical Sciences, Shiraz, Iran.
Students' Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
PLoS One. 2020 Oct 1;15(10):e0240102. doi: 10.1371/journal.pone.0240102. eCollection 2020.
In the 2017 ACC/AHA hypertension guidelines, a 10-year risk of more than 10% is considered for initiation of intensive blood pressure reduction. The current study aimed to determine which cut off limit of cardiovascular risk for starting intensive blood pressure reduction is beneficial.
A Secondary Analysis of Systolic Blood Pressure Intervention Trial (SPRINT).
Data from the SPRINT Trial was obtained from the NHLBI Data Repository Center. In the SPRINT, non-diabetic participants with SBP of ≥ 130 mmHg were randomly assigned to intensive and standard treatment arms with SBP targets of < 120 and < 140 mmHg, respectively. This study analyzed data from non-diabetic participants less than 75 years of age without cardiovascular or chronic kidney disease. The primary composite outcome was myocardial infarction, and other acute coronary syndromes, stroke, heart failure, or death from cardiovascular causes. Cox regression models were used to examine the risk of the occurrence of the SPRINT primary composite outcome. To identify the relationship between BP values and the log hazards, natural cubic spline functions were performed.
In the analysis, 4292 patients were enrolled. The results demonstrated a clear J-shaped relationship between the effect of intensive blood pressure control and the risk of CVD events and 10-year Framingham cardiovascular risk levels at a cut-off limit of approximately <7%.
This post-hoc secondary analyses of the SPRINT trial showed that a cut off value of more than 7% may be useful in selecting patients suitable for initiation of blood pressure reduction.
在 2017 年 ACC/AHA 高血压指南中,认为 10 年风险超过 10%时应开始强化降压。本研究旨在确定开始强化降压的心血管风险的切点下限是否有益。
收缩压干预试验(SPRINT)的二次分析。
SPRINT 试验的数据来自 NHLBI 数据存储中心。SPRINT 中,SBP≥130mmHg 的非糖尿病患者被随机分配到强化治疗组和标准治疗组,SBP 目标分别为<120mmHg 和<140mmHg。本研究分析了年龄<75 岁、无心血管疾病或慢性肾病的非糖尿病参与者的数据。主要复合结局是心肌梗死和其他急性冠状动脉综合征、卒中和心力衰竭或心血管原因导致的死亡。Cox 回归模型用于检查 SPRINT 主要复合结局的发生风险。为了确定 BP 值与对数风险之间的关系,进行了自然三次样条函数分析。
在分析中,共纳入 4292 名患者。结果表明,强化血压控制的效果与 CVD 事件风险和 Framingham 心血管风险 10 年水平(切点<7%左右)之间存在明显的 J 形关系。
SPRINT 试验的这项事后二次分析表明,>7%的截断值可能有助于选择适合开始降压的患者。